Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Microbiome

L’Oréal and Micreos target skin bacteria

by Melody M. Bomgardner
November 8, 2020 | A version of this story appeared in Volume 98, Issue 43

 

The cosmetics maker L’Oréal will license an endolysin enzyme developed by Dutch firm Micreos for use in microbiome-friendly skin-care products. The firms say the enzyme targets bacteria responsible for conditions such as inflammatory acne but, unlike antibiotics, does not harm beneficial bacteria. L’Oréal says the deal is part of its 15-year effort to better understand the role of the skin microbiome. Micreos is developing another endolysin as a pharmaceutical to treat atopic dermatitis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.